Kexing Biopharm (688136.SH) announced that its partner, Zhejiang Haichang Biotechnology Co., Ltd., has received notice from the European Commission that its introduced product, albumin-bound paclitaxel for injection (Apexelsin, hereinafter referred to as "albumin paclitaxel"), has been approved for listing by the European Commission.
Futubull mobile application account is required to access this feature.
The injectable albumin paclitaxel formulation has clinical advantages over ordinary paclitaxel injection and paclitaxel liposome injection, with improved safety and patient compliance and high clinical acceptance. Albumin paclitaxel is a recommended medication for the treatment of breast cancer, metastatic pancreatic cancer, and non-small cell lung cancer in the European Society for Medical Oncology guidelines. Over the past five years, the sales of albumin paclitaxel have gradually increased in the European market as the incidence of cancer in Europe has been on the rise. After albumin paclitaxel has received centralized approval for listing in the European Union this time, the company's albumin paclitaxel products can be sold in all EU countries. The EU market is an important part of the company's overseas commercialization strategy. The company actively promotes the layout and expansion of marketing channels in the EU market and has signed contracts with partners in 47 countries and regions, including developed markets such as the EU, Canada, and the United Kingdom, as well as emerging markets such as Brazil and Singapore. This approval will help the company to further accelerate the expansion of overseas markets, improve the company's market competitiveness, and have a positive impact on the company's operations in the future.
After albumin paclitaxel has received centralized approval for listing in the European Union this time, the company's albumin paclitaxel products can be sold in all EU countries. The EU market is an important part of the company's overseas commercialization strategy. The company actively promotes the layout and expansion of marketing channels in the EU market and has signed contracts with partners in 47 countries and regions, including developed markets such as the EU, Canada, and the United Kingdom, as well as emerging markets such as Brazil and Singapore. This approval will help the company to further accelerate the expansion of overseas markets, improve the company's market competitiveness, and have a positive impact on the company's operations in the future.